Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1989 1
1990 3
1991 1
1992 1
1993 1
1995 1
1996 2
1997 1
1998 3
1999 2
2000 7
2001 9
2002 13
2003 14
2004 7
2005 9
2006 13
2007 10
2008 10
2009 12
2010 18
2011 9
2012 11
2013 19
2014 19
2015 29
2016 32
2017 29
2018 43
2019 51
2020 54
2021 56
2022 67
2023 67
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Results by year

Filters applied: . Clear all
Page 1
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. Eslam M, et al. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278004 Free article. Review.
The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. ...
The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity …
ESPEN guideline on Clinical Nutrition in inflammatory bowel disease.
Bischoff SC, Bager P, Escher J, Forbes A, Hébuterne X, Hvas CL, Joly F, Klek S, Krznaric Z, Ockenga J, Schneider S, Shamir R, Stardelova K, Bender DV, Wierdsma N, Weimann A. Bischoff SC, et al. Clin Nutr. 2023 Mar;42(3):352-379. doi: 10.1016/j.clnu.2022.12.004. Epub 2023 Jan 13. Clin Nutr. 2023. PMID: 36739756
European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances.
Lott C, Truhlář A, Alfonzo A, Barelli A, González-Salvado V, Hinkelbein J, Nolan JP, Paal P, Perkins GD, Thies KC, Yeung J, Zideman DA, Soar J; ERC Special Circumstances Writing Group Collaborators. Lott C, et al. Resuscitation. 2021 Apr;161:152-219. doi: 10.1016/j.resuscitation.2021.02.011. Epub 2021 Mar 24. Resuscitation. 2021. PMID: 33773826
This section provides guidelines on the modifications required to basic and advanced life support for the prevention and treatment of cardiac arrest in special circumstances; specifically special causes (hypoxia, trauma, anaphylaxis, sepsis, hypo/hyperkalaemia and other electroly …
This section provides guidelines on the modifications required to basic and advanced life support for the prevention and treatment of cardia …
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
Foerster F, Gairing SJ, Müller L, Galle PR. Foerster F, et al. J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20. J Hepatol. 2022. PMID: 34555422 Review.
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important underlying aetiology of hepatocellular carcinoma (HCC). ...
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …
Acanthosis nigricans: A review.
Das A, Datta D, Kassir M, Wollina U, Galadari H, Lotti T, Jafferany M, Grabbe S, Goldust M. Das A, et al. J Cosmet Dermatol. 2020 Aug;19(8):1857-1865. doi: 10.1111/jocd.13544. J Cosmet Dermatol. 2020. PMID: 32516476 Review.
RESULTS: The pathophysiology of AN revolves around a multifactorial stimulation of proliferation of epidermal keratinocytes and dermal fibroblasts. Various types of AN include benign, obesity-associated, syndromic, malignant, acral, unilateral, medication-induced, and mixe …
RESULTS: The pathophysiology of AN revolves around a multifactorial stimulation of proliferation of epidermal keratinocytes and dermal fibro …
Health Benefits of Fasting and Caloric Restriction.
Golbidi S, Daiber A, Korac B, Li H, Essop MF, Laher I. Golbidi S, et al. Curr Diab Rep. 2017 Oct 23;17(12):123. doi: 10.1007/s11892-017-0951-7. Curr Diab Rep. 2017. PMID: 29063418 Review.
PURPOSE OF REVIEW: Obesity and obesity-related diseases, largely resulting from urbanization and behavioral changes, are now of global importance. ...
PURPOSE OF REVIEW: Obesity and obesity-related diseases, largely resulting from urbanization and behavioral changes, are now o …
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 Free article.
METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. RESU …
METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity …
European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.
Bischoff SC, Barazzoni R, Busetto L, Campmans-Kuijpers M, Cardinale V, Chermesh I, Eshraghian A, Kani HT, Khannoussi W, Lacaze L, Léon-Sanz M, Mendive JM, Müller MW, Ockenga J, Tacke F, Thorell A, Vranesic Bender D, Weimann A, Cuerda C. Bischoff SC, et al. United European Gastroenterol J. 2022 Sep;10(7):663-720. doi: 10.1002/ueg2.12280. Epub 2022 Aug 12. United European Gastroenterol J. 2022. PMID: 35959597 Free PMC article. Review.
RESULTS: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity - including sarcopenic obesity - is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty live …
RESULTS: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity …
Chronic venous insufficiency, cardiovascular disease, and mortality: a population study.
Prochaska JH, Arnold N, Falcke A, Kopp S, Schulz A, Buch G, Moll S, Panova-Noeva M, Jünger C, Eggebrecht L, Pfeiffer N, Beutel M, Binder H, Grabbe S, Lackner KJ, Ten Cate-Hoek A, Espinola-Klein C, Münzel T, Wild PS. Prochaska JH, et al. Eur Heart J. 2021 Oct 21;42(40):4157-4165. doi: 10.1093/eurheartj/ehab495. Eur Heart J. 2021. PMID: 34387673
The prevalence of telangiectasia/reticular, varicose veins, and CVI was 36.5% [95% confidence interval (CI), 35.6-37.4%], 13.3% [12.6-13.9%], and 40.8% [39.9-41.7%], respectively. Age, female sex, arterial hypertension, obesity, smoking, and clinically overt cardiovascular …
The prevalence of telangiectasia/reticular, varicose veins, and CVI was 36.5% [95% confidence interval (CI), 35.6-37.4%], 13.3% [12.6-13.9%] …
[Postoperative management].
Parzer V, Resl M, Stechemesser L, Wakolbinger M, Itariu B, Brix JM. Parzer V, et al. Wien Klin Wochenschr. 2023 Nov;135(Suppl 6):729-742. doi: 10.1007/s00508-023-02272-7. Epub 2023 Oct 11. Wien Klin Wochenschr. 2023. PMID: 37821696 Free PMC article. German.
Bariatric surgery results in significant weight loss, reduction or even remission of obesity-associated comorbidities, reduced mortality, and improved quality of life in many patients; however, obesity is a chronic disease, thus follow-up care is required after bari …
Bariatric surgery results in significant weight loss, reduction or even remission of obesity-associated comorbidities, reduced mortal …
568 results